Daniela Stranges GlaxoSmithKlein (GSK)

Ms. Daniela Stranges, Director, Basic Pharmaceutical Sciences (BPS), Drug Product, Vx Technical R&D, MDS, GlaxoSmithKlein (GSK) Daniela graduated in Chemistry and obtained a PhD in Chemical Sciences from the University of Florence, Italy. Since 2006, she has been part of the Technical Research and Development team at Novartis Vaccines (now GSK Vaccines). From 2011 to 2015, she served as Product and Process Development Leader for a vaccine candidate under development. In 2016, she contributed as the Product Understanding workstream leader to the GSK Quality by Design Integration initiative. From 2017 to 2020, Daniela led the Product Development team within the TRD Drug Product function. Since 2020, she has been Head of Basic Pharmaceutical Sciences in the Vaccines TRD Drug Product function. Her team is responsible for formulation discovery activities for various vaccine candidates in the discovery stage, including leading their developability and early formulation assessment. Additionally, the team pioneers the discovery and development of new delivery systems and technologies, serving as a crucial link between preclinical research and Technical R&D. Over the course of her career, Daniela has played a key role in the development of numerous candidate vaccines that have been, and are currently, tested in clinical settings.